Sun Pharma's Q2 nos draw price upgrades, stock hits 7-yr high https://ift.tt/YzEmcTA of India's largest pharmaceutical company, which surged to its seven-year high earlier on Wednesday, advanced 1.45% to close at ₹1,051.60. It touched a high of ₹1,070.95 before giving up some of its gains. Analysts have a median target price of ₹1,135.28 per share. That translates roughly into gains of 8.3% from the current market price.
Government's cash surplus tops Rs 3.4 lakh crore https://ift.tt/54P3HSG from the deceleration in government spending, higher direct tax collections and a likely sharp rise in issuances of Treasury Bills by the Centre in FY24 were factors pushing up the government's cash balances, analysts said. The flow of government cash balances to and from the banking system is a key factor that influences liquidity conditions.
Comments
Post a Comment